Brain overgrowth in disorders of RTK-PI3K-AKT signaling: a mosaic of malformations.

Disorders of brain overgrowth are significant causes of intractable epilepsy, intellectual disability, autism, and other complex neurological problems. The pathology of these disorders is sometimes striking and characteristic, as in hemimegalencephaly, but can also be subtle, as in autism. Recent genetic studies have shown that many diverse forms of brain overgrowth are caused by de novo mutations that increase activity in the receptor tyrosine kinase (RTK)-phosphatidylinositol-3-kinase (PI3K)-AKT signaling pathway, a key mediator of signaling by growth factors in the developing brain, such as fibroblast growth factors. In cases where mutations arise in postzygotic embryos, brain regions exhibit mosaic pathology that reflects the distribution of mutant cells, ranging from focal cortical dysplasia to lobar or hemispheric overgrowth. In turn, the histopathology of these disorders is also remarkably varied. The common underlying mechanisms of RTK-PI3K-AKT overactivation suggest new possibilities for drugs that inhibit this pathway.

[1]  Joseph B Hiatt,et al.  PI3K/AKT pathway mutations cause a spectrum of brain malformations from megalencephaly to focal cortical dysplasia. , 2015, Brain : a journal of neurology.

[2]  Dagmar Wieczorek,et al.  De novo CCND2 mutations leading to stabilization of cyclin D2 cause megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome , 2014, Nature Genetics.

[3]  C. Walsh,et al.  Somatic mutations in cerebral cortical malformations. , 2014, The New England journal of medicine.

[4]  C. Walsh,et al.  Somatic Mutation, Genomic Variation, and Neurological Disease , 2013, Science.

[5]  Gary W Mathern,et al.  Hemimegalencephaly, a paradigm for somatic postzygotic neurodevelopmental disorders. , 2013, Current opinion in neurology.

[6]  Eleonora Aronica,et al.  Detection of human papillomavirus in human focal cortical dysplasia type IIB , 2012, Annals of neurology.

[7]  J. O’Kusky,et al.  Neurodevelopmental effects of insulin-like growth factor signaling , 2012, Frontiers in Neuroendocrinology.

[8]  S. Gabriel,et al.  De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly , 2012, Nature Genetics.

[9]  J. Shendure,et al.  De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes , 2012, Nature Genetics.

[10]  Maria K. Lehtinen,et al.  Somatic Activation of AKT3 Causes Hemispheric Developmental Brain Malformations , 2012, Neuron.

[11]  P. Hawkins,et al.  PI3K signalling: the path to discovery and understanding , 2012, Nature Reviews Molecular Cell Biology.

[12]  J. Stockman,et al.  Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis , 2012 .

[13]  Jamie K Teer,et al.  A mosaic activating mutation in AKT1 associated with the Proteus syndrome. , 2011, The New England journal of medicine.

[14]  Maria K. Lehtinen,et al.  The Cerebrospinal Fluid Provides a Proliferative Niche for Neural Progenitor Cells , 2011, Neuron.

[15]  Maria Thom,et al.  The clinicopathologic spectrum of focal cortical dysplasias: A consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission 1 , 2011, Epilepsia.

[16]  Jeffrey A. Engelman,et al.  Targeting PI3K signalling in cancer: opportunities, challenges and limitations , 2009, Nature Reviews Cancer.

[17]  R. Hevner,et al.  Fibroblast growth factor signaling in development of the cerebral cortex , 2009, Development, growth & differentiation.

[18]  P. Ye,et al.  Expanding the mind: insulin-like growth factor I and brain development. , 2008, Endocrinology.

[19]  A. D'ercole,et al.  Minireview: Expanding the Mind: Insulin-Like Growth Factor I and Brain Development , 2008 .

[20]  A. Goffinet,et al.  Reelin Signals through Phosphatidylinositol 3-Kinase and Akt To Control Cortical Development and through mTor To Regulate Dendritic Growth , 2007, Molecular and Cellular Biology.

[21]  C. Der,et al.  Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer , 2007, Oncogene.

[22]  A. Olney Macrocephaly syndromes. , 2007, Seminars in pediatric neurology.

[23]  C. Elger,et al.  Activation of Akt independent of PTEN and CTMP tumor-suppressor gene mutations in epilepsy-associated Taylor-type focal cortical dysplasias , 2006, Acta Neuropathologica.

[24]  C. Cepeda,et al.  Contralateral hemimicrencephaly and clinical-pathological correlations in children with hemimegalencephaly. , 2006, Brain : a journal of neurology.

[25]  P. Ye,et al.  Insulin‐like growth factor actions during development of neural stem cells and progenitors in the central nervous system , 2006, Journal of neuroscience research.

[26]  R. Hevner The cerebral cortex malformation in thanatophoric dysplasia: neuropathology and pathogenesis , 2005, Acta Neuropathologica.

[27]  A. V. van Huffelen,et al.  Tuberous sclerosis complex and its founders , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[28]  H. Sarnat,et al.  Hemimegalencephaly: part 2. Neuropathology suggests a disorder of cellular lineage. , 2003, Journal of child neurology.

[29]  R. Houlston,et al.  Overgrowth syndromes: is dysfunctional PI3-kinase signalling a unifying mechanism? , 2003, European Journal of Human Genetics.

[30]  A. Munnich,et al.  Overgrowth and trisomy 15q26.1-qter including the IGF1 receptor gene: report of two families and review of the literature , 2002, European Journal of Human Genetics.

[31]  L. Hoefsloot,et al.  PTEN mutation in a family with Cowden syndrome and autism. , 2001, American journal of medical genetics.

[32]  Ruth A. Carper,et al.  Unusual brain growth patterns in early life in patients with autistic disorder , 2001, Neurology.

[33]  R. Dietrich,et al.  The Proteus syndrome: CNS manifestations. , 1998, AJNR. American journal of neuroradiology.

[34]  S Povey,et al.  Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. , 1997, Science.

[35]  D. Rimoin,et al.  Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3 , 1995, Nature Genetics.

[36]  W. Reardon,et al.  Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome , 1995, Nature Genetics.

[37]  S. Thomas,et al.  Identification and characterization of the tuberous sclerosis gene on chromosome 16 , 1993, Cell.

[38]  S. Kreiborg,et al.  The central nervous system in the Apert syndrome. , 1990, American journal of medical genetics.

[39]  M. Blackbourn Tuberous Sclerosis and the Autistic Syndrome , 1987, British Journal of Psychiatry.

[40]  J. Aicardi,et al.  [An unusual cerebral malformation associated with thanatophoric dwarfism]. , 1971, Revue neurologique (Paris).

[41]  M. Partington,et al.  Cloverleaf skull and thanatophoric dwarfism , 1971, Archives of disease in childhood.

[42]  M A Falconer,et al.  Focal dysplasia of the cerebral cortex in epilepsy , 1971, Journal of neurology, neurosurgery, and psychiatry.

[43]  J. Sims On Hypertrophy and Atrophy of the Brain. , 1835, Medico-chirurgical transactions.